View Future GrowthTranslational Development Acquisition 과거 순이익 실적과거 기준 점검 4/6Translational Development Acquisition의 연간 평균 수익은 110.6%였으며, Capital Markets 산업의 수익은 연간 5.8% 증가했습니다.핵심 정보110.63%순이익 성장률93.67%주당순이익(EPS) 성장률Capital Markets 산업 성장률10.26%매출 성장률n/a자기자본이익률n/a순이익률n/a최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates속보 • Jul 08ProLogium Advances De-SPAC Merger Process With TDAC After SEC F-4 FilingTranslational Development Acquisition announced that ProLogium has filed its initial Form F-4 registration statement with the SEC, a key step in progressing their planned de-SPAC merger. The F-4 filing provides the SEC and investors with more detailed information on ProLogium’s history and the proposed business combination, moving the transaction further along the regulatory process. TDAC units last traded at $11.60, with the stock down 27.2% over the past 30 days, indicating recent share price pressure despite the merger process advancing. This filing marks a formal point where investors can expect more comprehensive disclosures about ProLogium and the merger terms. These disclosures can help in assessing how the combined company might look and what deal risks remain, including regulatory review, shareholder approval, and any potential changes to the transaction structure.Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorates as stock falls 28%After last week's 28% share price decline to US$11.50, the stock trades at a trailing P/E ratio of 40.6x. Average trailing P/E is 40x in the Capital Markets industry in the US. Total returns to shareholders of 11% over the past year.공시 • May 29Prologium Holdings Inc. agreed to acquire Translational Development Acquisition Corp. (NasdaqGM:TDAC.U) from TDAC Partners LLC for approximately $3.8 billion in a reverse merger transaction.Prologium Holdings Inc. ntered into a definitive agreement to acquire Translational Development Acquisition Corp. (NasdaqGM:TDAC.U) from TDAC Partners LLC for approximately $3.8 billion in a reverse merger transaction on May 27, 2026. The transaction values Prologium at approximately $3.8 billion on a pre-money, net cash-free basis. Upon closing, ProLogium will own 92% of the combined company with SPAC & PIPE Investors owning 7%, and SPAC Sponsor owning 1%. Upon completion, the combined company is expected to be named ProLogium Technology and to be listed on Nasdaq under the ticker symbol "PRLG". As part of the transaction, the post-closing board shall consist of nine directors whom one individual is expected to be Michael Hoffman. The consummation of the transaction is conditioned upon, among other things: (i) approval for listing of Prologium Class A Ordinary Shares and warrants contemplated to be listed pursuant to the Business Combination Agreement on Nasdaq; (ii) the absence of any governmental order enjoining, restraining, prohibiting or otherwise making illegal the consummation of the Business Combination; (iii) receipt of the required approval by TDAC shareholders; (iv) receipt of the required approval by Prologium shareholders; (v) the effectiveness of the registration statement to be filed by Prologium under the Securities Act of 1933, as amended; (vi) the Second Merger Surviving Company, as successor to TDAC, having at least $5,000,001 of net tangible assets after the consummation of the Business Combination and the closing of any TDAC shareholder redemptions; (vii) completion of the Recapitalization in accordance with the Business Combination Agreement; (viii) lock-up agreement; (ix) registration rights agreement; and (x) Available Cash, as defined in the Business Combination Agreement, being greater than or equal to $250 million. The boards of directors of both ProLogium and TDAC have approved the Transaction, which is expected to close in the second half of 2026. Venable LLP acted as legal advisor for Translational Development Acquisition Corp. Sullivan & Cromwell LLP acted as legal advisor for Prologium Holdings Inc. BTIG, LLC acted as financial advisor for Translational Development Acquisition Corp. Cohen & Company Capital Markets, LLC acted as financial advisor for Prologium Holdings Inc. LCS & Partners acted as legal advisor for Prologium Holdings Inc.Board Change • May 26High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Chairman of the Board & CEO Michael M. Hoffman is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.공시 • Dec 24Translational Development Acquisition Corp. has completed an IPO in the amount of $150 million.Translational Development Acquisition Corp. has completed an IPO in the amount of $150 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 15,000,000 Price\Range: $10 Discount Per Security: $0.55 Transaction Features: Blank Check Blind Pool Company매출 및 비용 세부 내역Translational Development Acquisition가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqGM:TDAC.U 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 26061031 Dec 25061030 Sep 25051030 Jun 25031031 Mar 25011031 Dec 24000030 Sep 240-11030 Jun 24000031 Mar 24000031 Dec 230000양질의 수익: TDAC.U는 고품질 수익을 보유하고 있습니다.이익 마진 증가: 지난 1년 동안 TDAC.U의 이익률이 개선되었는지 판단하기에 데이터가 부족합니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: TDAC.U의 수익은 지난 5년 동안 연평균 110.6%로 크게 증가했습니다.성장 가속화: 지난 1년간 TDAC.U 의 수익 증가율(339.7%)은 연간 평균(110.6%)을 초과합니다.수익 대 산업: TDAC.U의 지난 1년 수익 증가율(339.7%)은 Capital Markets 업계의 38.3%를 상회했습니다.자기자본이익률높은 ROE: TDAC.U의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YDiversified-financials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/09 15:46종가2026/07/09 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Translational Development Acquisition Corp.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
속보 • Jul 08ProLogium Advances De-SPAC Merger Process With TDAC After SEC F-4 FilingTranslational Development Acquisition announced that ProLogium has filed its initial Form F-4 registration statement with the SEC, a key step in progressing their planned de-SPAC merger. The F-4 filing provides the SEC and investors with more detailed information on ProLogium’s history and the proposed business combination, moving the transaction further along the regulatory process. TDAC units last traded at $11.60, with the stock down 27.2% over the past 30 days, indicating recent share price pressure despite the merger process advancing. This filing marks a formal point where investors can expect more comprehensive disclosures about ProLogium and the merger terms. These disclosures can help in assessing how the combined company might look and what deal risks remain, including regulatory review, shareholder approval, and any potential changes to the transaction structure.
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorates as stock falls 28%After last week's 28% share price decline to US$11.50, the stock trades at a trailing P/E ratio of 40.6x. Average trailing P/E is 40x in the Capital Markets industry in the US. Total returns to shareholders of 11% over the past year.
공시 • May 29Prologium Holdings Inc. agreed to acquire Translational Development Acquisition Corp. (NasdaqGM:TDAC.U) from TDAC Partners LLC for approximately $3.8 billion in a reverse merger transaction.Prologium Holdings Inc. ntered into a definitive agreement to acquire Translational Development Acquisition Corp. (NasdaqGM:TDAC.U) from TDAC Partners LLC for approximately $3.8 billion in a reverse merger transaction on May 27, 2026. The transaction values Prologium at approximately $3.8 billion on a pre-money, net cash-free basis. Upon closing, ProLogium will own 92% of the combined company with SPAC & PIPE Investors owning 7%, and SPAC Sponsor owning 1%. Upon completion, the combined company is expected to be named ProLogium Technology and to be listed on Nasdaq under the ticker symbol "PRLG". As part of the transaction, the post-closing board shall consist of nine directors whom one individual is expected to be Michael Hoffman. The consummation of the transaction is conditioned upon, among other things: (i) approval for listing of Prologium Class A Ordinary Shares and warrants contemplated to be listed pursuant to the Business Combination Agreement on Nasdaq; (ii) the absence of any governmental order enjoining, restraining, prohibiting or otherwise making illegal the consummation of the Business Combination; (iii) receipt of the required approval by TDAC shareholders; (iv) receipt of the required approval by Prologium shareholders; (v) the effectiveness of the registration statement to be filed by Prologium under the Securities Act of 1933, as amended; (vi) the Second Merger Surviving Company, as successor to TDAC, having at least $5,000,001 of net tangible assets after the consummation of the Business Combination and the closing of any TDAC shareholder redemptions; (vii) completion of the Recapitalization in accordance with the Business Combination Agreement; (viii) lock-up agreement; (ix) registration rights agreement; and (x) Available Cash, as defined in the Business Combination Agreement, being greater than or equal to $250 million. The boards of directors of both ProLogium and TDAC have approved the Transaction, which is expected to close in the second half of 2026. Venable LLP acted as legal advisor for Translational Development Acquisition Corp. Sullivan & Cromwell LLP acted as legal advisor for Prologium Holdings Inc. BTIG, LLC acted as financial advisor for Translational Development Acquisition Corp. Cohen & Company Capital Markets, LLC acted as financial advisor for Prologium Holdings Inc. LCS & Partners acted as legal advisor for Prologium Holdings Inc.
Board Change • May 26High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Chairman of the Board & CEO Michael M. Hoffman is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
공시 • Dec 24Translational Development Acquisition Corp. has completed an IPO in the amount of $150 million.Translational Development Acquisition Corp. has completed an IPO in the amount of $150 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 15,000,000 Price\Range: $10 Discount Per Security: $0.55 Transaction Features: Blank Check Blind Pool Company